MERRF syndrome
Methodology & AI Transparency ⓘ
MERRF syndrome Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Weight Management & Metabolic Syndrome practice, MERRF syndrome (ICD-10 E88.42) is stratified through fasting cardiometabolic panels [MERRF syndrome E88.42], pairing targeted symptom control with longitudinal HOMA-IR Insulin Resistance in MERRF syndrome (E88.42: Index) surveillance.
- 2 Real-world patient consensus: Federal ICD-10-CM code E88.42 categorizes MERRF syndrome under Weight Management & Metabolic Syndrome.
- 3 Typical cash cost range: Primary evaluation for MERRF syndrome incorporates fasting cardiometabolic panels [MERRF syndrome E88.42] and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in MERRF syndrome: maintaining Waist-to-Height Ratio [MERRF syndrome E88.42] within < 0.50 (E88.42).
Ask our AI Specialists anything about MERRF syndrome
What Is MERRF syndrome?
Within Weight Management & Metabolic Syndrome practice, MERRF syndrome (ICD-10 E88.42) is stratified through fasting cardiometabolic panels [MERRF syndrome E88.42], pairing targeted symptom control with longitudinal HOMA-IR Insulin Resistance in MERRF syndrome (E88.42: Index) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying MERRF syndrome (code E88.42) is ectopic hepatic lipid in MERRF syndrome (E88.42: storage), which Weight Management & Metabolic Syndrome clinicians address while surveilling Waist-to-Height Ratio [MERRF syndrome E88.42] (< 0.50 (E88.42)).
Common Symptoms & Clinical Signs
- • Presentation of MERRF syndrome (E88.42): co-existing blood pressure, in MERRF syndrome (E88.42: triglyceride, or fasting)
- • Secondary MERRF syndrome clinical sign: joint load discomfort in MERRF syndrome (E88.42: in knees, hips,)
- • Symptom flares in MERRF syndrome correlating with Waist-to-Height Ratio [MERRF syndrome E88.42] deviation outside < 0.50 (E88.42)
- • Functional weight & metabolism impact requiring fasting cardiometabolic panels [MERRF syndrome E88.42] evaluation (E88.42)
MERRF syndrome Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E88.42 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Weight Management & Metabolic Syndrome | NLM Clinical Tables |
| Diagnostic / Lab Marker: Waist-to-Height Ratio [MERRF syndrome E88.42] | < 0.50 (E88.42) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: HOMA-IR Insulin Resistance in MERRF syndrome (E88.42: Index) | < 1.4 (E88.42) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: ALT & Fasting in MERRF syndrome (E88.42: Triglycerides) | ALT < 25 U/L; TG < 100 mg/dL (E88.42) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for MERRF syndrome
Treatment selection for MERRF syndrome depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (MERRF syndrome)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Safety, tolerability and sustained weight loss over 2 years with the once-daily: What a 564-Participant Study Found Liraglutide is well tolerated, sustains weight loss over 2 years and improves heart and blood vessel risk factors. International journal of obesity (2005) • 2012-06-15 • Randomized Controlled Trial | N = 564 | 93/100 | PMID 21844879 ↗ |
| What the Latest Evidence Really Says About GLP-1 receptor agonists as an add-on booster to bariatric surgery for weight loss However, more long-term randomized controlled trials are needed to confirm these findings and further assess its effectiveness. Langenbeck's archives of surgery • 2025-10-10 • Meta-Analysis | Multi-cohort | 92/100 | PMID 41071360 ↗ |
| Can This Approach Help? Inside the Latest Research on Liraglutide on weight, satiation, and gastric functions in obesity: a randomised, Effects of liraglutide on weight loss are associated with delay in gastric emptying of solids; measurement of gastric emptying (eg, at 5 weeks of treatment) may be a biomarker of responsiveness and may help to select... The lancet. Gastroenterology & hepatology • 2017-12-15 • Randomized Controlled Trial | N = 40 | 88/100 | PMID 28958851 ↗ |
| New Insights on Impact of patient weight status on healthcare students' attitudes: Two: What a 281-Participant Study Found Weight stigma is evident among healthcare students and can affect healthcare advice. British journal of health psychology • 2026-11-15 • Randomized Controlled Trial | N = 281 | 87/100 | PMID 42952245 ↗ |
| What the Latest Evidence Really Says About Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Females lost more weight than males when treated with GLP-1RAs for weight reduction. Journal of diabetes • 2025-03-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 40040445 ↗ |
MERRF syndrome Patient Community & “People Like Me” Threads
Filter MERRF syndrome community threads and patient logs by age, biological sex, dosage, and treatment duration.